有机化学 ›› 2022, Vol. 42 ›› Issue (7): 1974-1999.DOI: 10.6023/cjoc202202011 上一篇    下一篇

综述与进展

靶向新型冠状病毒SARS-CoV-2主蛋白酶的抗病毒药物研究进展

王春霞a,b, 胡晓东b, 许斌a,*(), 曹春阳b,*()   

  1. a上海大学理学院化学系 上海 200444
    b中国科学院上海有机化学研究所 生命有机化学国家重点实验室 上海 200032
  • 收稿日期:2022-02-16 修回日期:2022-04-06 发布日期:2022-08-09
  • 通讯作者: 许斌, 曹春阳
  • 基金资助:
    科技部重点研发项目(2017YFE0108200); 中国科学院战略性先导科技专项(XDB20000000); 国家自然科学基金(21977110); 国家自然科学基金(22177127); 国家自然科学基金(91753119); 及中国科学院分子合成卓越中心(FZHCZY020600)

Research Progress of Antiviral Drug Targeting the Main Protease of SARS-CoV-2

Chunxia Wanga,b, Xiaodong Hub, Bin Xua(), Chunyang Caob()   

  1. aDepartment of Chemistry, College of Science, Shanghai University, Shanghai 200444
    bState Key Lab of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032
  • Received:2022-02-16 Revised:2022-04-06 Published:2022-08-09
  • Contact: Bin Xu, Chunyang Cao
  • Supported by:
    National Key Research and Development Program of Ministry of Science and Technology(2017YFE0108200); Chinese Academy of Sciences Strategic Priority Research Program(XDB20000000); National Natural Science Foundation of China(21977110); National Natural Science Foundation of China(22177127); National Natural Science Foundation of China(91753119); Center for Excellence in Molecular Synthesis, Chinese Academy of Sciences(FZHCZY020600)

2019年底, 新型冠状病毒SARS-CoV-2导致的新冠肺炎大流行对世界人口产生了严重的威胁. 目前一些有效的疫苗已被批准并广泛使用, 但考虑到冠状病毒的高突变性, 这一干预措施的长期有效性和安全性存在争议. 此外一些抗病毒药物显示出较好的效果, 但其安全性与普适性暂未得到更多的数据支持. 冠状病毒主蛋白酶(3CLpro)是冠状病毒家族中一种特殊的半胱氨酸蛋白酶, 负责处理病毒多蛋白产生成熟的非结构蛋白, 在冠状病毒生命周期中起重要作用, 而且具有高度保守性, 因此其是一个重要的药物靶点. 结构研究为这种蛋白酶的功能和合理抑制剂设计的结构基础提供了有价值的见解. 综述了SARS-CoV-2 3CLpro的结构和迄今为止针对3CLpro的亮点抑制剂的研究进展, 并详细介绍了抑制剂与3CLpro的结合方式和构效关系. 此外, 还广泛研究了这些抑制剂的抗病毒活性、ADMET和动物试验.

关键词: 新冠肺炎, 新型冠状病毒, 主蛋白酶抑制剂, 抗病毒药物发现

The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 in late 2019 posed a serious threat to the world population. Some effective vaccines are currently approved and widely used, but the long-term efficacy and safety of this intervention is controversial given the highly mutagenic nature of the coronavirus. In addition, some antiviral drugs show better effects, but their safety and universality have not been supported by more data. Coronavirus main protease (3CLpro) is a special cysteine protease in the coronavirus family, responsible for processing viral polyproteins to produce yield mature non-structural proteins, which play an important role in the life cycle of coronaviruses and are highly conserved, and therefor is considered as a prominent target for antiviral drug. Strucure studies provide valuable insight into the function of this protease and structural basis of rational inhibitor design. This paper reviews the structure of SARS-CoV-2 3CLpro and the research progress of bright spot inhibitors targeting 3CLpro so far, and introduces binding mode and the structure-activity relationships of inhibitors and 3CLpro in detail. Additionally, we broadly examine available antiviral activity, ADMET and animal tests of these inhibitors.

Key words: COVID-19, SARS-CoV-2, 3CLpro inhibitor, antivirals drug discovery